newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025

  • Ascentage Pharma Group International (NASDAQ: AAPG, HKEX: 6855) announced its management will participate in two investor conferences in November 2025.
  • The company will attend the Goldman Sachs APAC Healthcare Corporate Day 2025 for one-on-one and group investor meetings on November 5.
  • The company will present at the Stifel 2025 Healthcare Conference on November 13 at 2:40 pm EST.
  • Ascentage Pharma is a global, commercial-stage biopharmaceutical company developing therapies for unmet medical needs in cancer.
  • The company's pipeline includes inhibitors targeting Bcl-2, MDM2, p53, and next-generation kinase inhibitors.
  • Olverembatinib is the first approved product, a third-generation BCR-ABL1 inhibitor approved in China for chronic myelogenous leukemia (CML) patients with T315I mutations or resistance to first/second-generation TKIs.
  • Olverembatinib indications are covered by the China National Reimbursement Drug List (NRDL), with ongoing FDA-cleared Phase III trials POLARIS-1 (Ph+ALL), POLARIS-2 (CML), and POLARIS-3 (SDH-deficient GIST).
  • Lisaftoclax is the second approved product, a Bcl-2 inhibitor approved by China's NMPA for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) previously treated with BTK inhibitors.
  • Four global registrational Phase III trials for Lisaftoclax are underway: GLORA (CLL/SLL with suboptimal response to BTK inhibitors), GLORA-2 (newly diagnosed CLL/SLL), GLORA-3 (elderly/unfit acute myeloid leukemia), and GLORA-4 (newly diagnosed higher-risk myelodysplastic syndrome).
  • The company holds global intellectual property rights and has partnerships with Takeda, AstraZeneca, Merck, Pfizer, Innovent, Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute, and the University of Michigan.